MoonLake Immunotherapeutics

MLTX

$1.14B

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaZUG100 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 27, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

⭐Phase 3Next

Sonelokimab Phase 3 Results Expected

Mar 27, 2026Sonelokimab35

Primary completion for Sonelokimab trial (NCT06768671) in Hidradenitis Suppurativa

Source

⭐Phase 3

Risankizumab Phase 3 Results Expected

Jan 15, 2027Risankizumab600

Primary completion for Risankizumab trial (NCT06641089) in Arthritis, Psoriatic

Source

⭐Phase 3

Sonelokimab Phase 3 Results Expected

Jan 15, 2027Sonelokimab960

Primary completion for Sonelokimab trial (NCT06641076) in Arthritis, Psoriatic

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Sonelokimab

Phase 3

Hidradenitis Suppurativa

Risankizumab

Phase 3

Arthritis, Psoriatic

Adalimumab

Phase 2

Arthritis, Psoriatic

Sonelokimab (M1095)

Phase 2

Hidradenitis Suppurativa

Drug Name	Phase	Indication	Designations
Sonelokimab	Phase 3	Hidradenitis Suppurativa	-
Risankizumab	Phase 3	Arthritis, Psoriatic	-
Adalimumab	Phase 2	Arthritis, Psoriatic	-
Sonelokimab (M1095)	Phase 2	Hidradenitis Suppurativa	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

MLTX News